Autres langues Tibet Duo Rui Pharmaceutical Co., Ltd.

Actions

301075

CNE100004RW5

Produits pharmaceutiques

Cours en clôture Shenzhen S.E. Autres places de cotation 07/07/2026			Varia. 5j.	Varia. 1 janv.
60,15 ^CNY	+0,65 %		+3,17 %	+0,80 %

28/04	Tibet Duo Rui Pharmaceutical Co., Ltd. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
23/04	Tibet Duo Rui Pharmaceutical Co., Ltd. publie ses résultats annuels pour l'exercice clos le 31 décembre 2025	CI

Autres langues

28/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
23/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.
27/02	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.
24/02	Trading in Tibet Duo Rui Pharmaceutical's shares to halt
21/01	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.
05/12	Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.
23/10/25	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
13/10/25	Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million.
29/09/25	Duorui Pharma Expects Control Change Amid Parents' Plan
29/09/25	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2025.
28/09/25	Trading in Tibet Duo Rui Pharmaceutical's shares to halt
26/08/25	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
24/04/25	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
17/04/25	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
04/11/24	Hubei Qingsong Yueyue Pharmaceutical Co., Ltd. agreed to acquire 5.66% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 68.8 million.
24/10/24	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
11/10/24	Duorui Pharmaceutical to Acquire 70% Stake in Frontier Jianling Biotechnology for 271 Million Yuan
29/09/24	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2024.
26/09/24	Xiamen Ruidilian Medical Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Tibet Duo Rui Pharmaceutical Co., Ltd., Henan Zhengxinyuan Medical Technology Co., Ltd. and another investor
28/08/24	Tibet Duo Rui Pharmaceutical Co., Ltd. signed an investment intent agreement to acquire 70% stake in Sichuan Frontier Biopharmaceutical Co., Ltd. from Frontier Biotechnologies Inc..
27/08/24	Tibet Duo Rui Pharmaceutical Co., Ltd. agreed to acquire 70% stake in Shanghai Frontier Jianling Biotechnology Co., Ltd. from Frontier Biotechnologies Inc..
26/08/24	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024